Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-induced sustained B-cell depletion in refractory pediatric nephrotic syndrome
ChiCTR2600124282Phase 4Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in nephrosis, nephritic syndrome, IgA nephropathy (IgAN) and 2 more (4 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Duration of complete or sustained remission, Reasons for recurrence and 2 more. Started May 2026; status: recruiting.
02
Drugs
rituximab
03
Conditions
nephrosisnephritic syndromeIgA nephropathy (IgAN)membranous glomerulonephritis (MGN)membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on ChiCTR2600124282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124282.